Acadia Healthcare Q3 2021 Earnings Report
Key Takeaways
Acadia Healthcare reported a revenue of $587.6 million for Q3 2021, a 7.2% increase compared to $548.0 million in Q3 2020. Net income attributable to Acadia stockholders was $66.1 million, or $0.73 per diluted share, compared to $37.0 million, or $0.42 per diluted share, for the same period last year. The company faced challenges from Hurricane Ida and the Delta variant of COVID-19, but continued to execute on strategic initiatives, adding 104 beds and opening two new CTCs.
Revenue for the third quarter of 2021 was $587.6 million, compared to $548.0 million for the third quarter of 2020.
Net income attributable to Acadia stockholders for the third quarter of 2021 was $66.1 million, or $0.73 per diluted share.
Same facility revenue increased 7.9% compared with the third quarter of 2020.
The company added 104 beds to its operations and opened two new comprehensive treatment centers (CTCs) during the third quarter.
Acadia Healthcare
Acadia Healthcare
Forward Guidance
Acadia narrowed its financial guidance for 2021, within previously announced ranges. Revenue is expected to be in the range of $2.295 billion to $2.315 billion. Adjusted EBITDA is projected to be in the range of $537 million to $547 million. Adjusted earnings per diluted share are anticipated to be in the range of $2.51 to $2.59. Operating cash flows are expected to be in the range of $290 million to $325 million. Total capital expenditures are projected to be in the range of $210 million to $230 million.